Peptide questions · Orforglipron
Orforglipron side effects: what studies and users report
Reviewed Evidence: EstablishedPublished by PepVault
The side effects most commonly reported for orforglipron are nausea, constipation and diarrhea, among 8 the library lists; the library’s evidence on it includes controlled trials in people.
Its safety note opens: The Foundayo label carries the GLP-1 class boxed warning for thyroid C-cell tumors.
What is commonly reported with orforglipron
- Nausea
- Constipation
- Diarrhea
- Vomiting
- Indigestion
- Abdominal pain
- Headache
- Burping
Common here means the library lists it among the effects people most often report; the list doesn’t say how often each one happens.
| Effect | Also listed for (of 24) |
|---|---|
| Nausea | 21: Semaglutide, Semaglutide (oral), Tirzepatide, Retatrutide and 17 more |
| Constipation | 13: Semaglutide, Semaglutide (oral), Tirzepatide, Retatrutide and 9 more |
| Diarrhea | 20: Semaglutide, Semaglutide (oral), Tirzepatide, Retatrutide and 16 more |
| Vomiting | 18: Semaglutide, Semaglutide (oral), Tirzepatide, Retatrutide and 14 more |
| Indigestion | 2: Dulaglutide, Exenatide |
| Abdominal pain | 7: Semaglutide (oral), Tirzepatide, Retatrutide, Dulaglutide and 3 more |
| Headache | 3: Exenatide, Setmelanotide, Pramlintide |
| Burping | None: listed for Orforglipron alone |

Model. Individual results vary.
Which orforglipron side effects the metabolic & GLP-1 group shares
Across the 25 metabolic & GLP-1 compounds in the library, the effects listed most often are nausea (22 of 25), diarrhea (21 of 25), vomiting (19 of 25) and constipation (14 of 25). Orforglipron shares 7 of its 8 listed effects with at least one other metabolic & GLP-1 compound; burping is listed for orforglipron alone.
What the orforglipron safety notes say
The library’s safety note
The Foundayo label carries the GLP-1 class boxed warning for thyroid C-cell tumors. Other GLP-1 drugs caused them in rodents; orforglipron is not active at the rat or mouse receptor and caused none there, and the human relevance of the finding is not known, so the label rules it out for anyone with a personal or family history of medullary thyroid carcinoma or MEN 2. Its other warnings: acute pancreatitis (confirmed in 6 people on orforglipron vs 1 on placebo in the weight trials), severe GI reactions (about 3% vs 1%), kidney injury from dehydration, low blood sugar (mainly alongside insulin or a sulfonylurea), allergic reactions, a temporary worsening of diabetic retinopathy, gallbladder disease, and food reaching the lungs under anesthesia. Resting heart rate rose 4 to 5 beats per minute on average, and hair shedding, tied to weight loss, was more common in women (7% vs 3% on placebo). These are label findings; review them with your clinician.
The library’s interaction note
The label advises against combining it with another GLP-1 drug. Orforglipron is cleared mainly by the liver enzyme CYP3A4, so some medicines change its levels: the label caps it at 9 mg alongside a strong CYP3A4 inhibitor (clarithromycin raised exposure 3.5-fold), advises avoiding strong inhibitors that also block OATP1B (such as ritonavir) and strong CYP3A4 inducers (carbamazepine cut exposure by 82%), and limits simvastatin to 20 mg a day (orforglipron doubled its active form). Slower stomach emptying may weaken birth-control pills: the label suggests a non-oral or backup method for 30 days after starting and after each step-up. With insulin or a sulfonylurea, those doses are often lowered to limit low blood sugar. Review all your medicines with your clinician or pharmacist.
These are reference notes from published research and reported use, not advice for a person: discuss your own situation with your clinician.
Where the orforglipron reports come from
The library rates the evidence on orforglipron as established: clinical trials or FDA-approved use exist.
Of the library’s 8 research notes on orforglipron, 8 rest on randomized trials.
Our 5 study pages on orforglipron: 4 randomized trials and 1 clinical trial.
So orforglipron has controlled trials in people to set its listed effects against.
What our orforglipron study pages report on safety
Orforglipron: heart events no worse than insulin in ACHIEVE-4
Randomized trial, human, 2026: Gut side effects were reported in 62.1% on orforglipron vs 14.2% on insulin glargine, and were the most common reason people stopped orforglipron, while clinically significant or severe low blood sugar occurred in 6.8% vs 19.2%. In adults with type 2 diabetes and high heart risk, orforglipron did not raise major heart events compared with insulin glargine over about 2 years, with more gut side effects but fewer low blood sugar episodes.
Orforglipron: 9.6% weight loss at 72 weeks in ATTAIN-2
Randomized trial, human, 2026: The most common side effects were mild-to-moderate stomach and gut problems, mostly while the dose was being stepped up, and 6.1-9.9% of people on orforglipron stopped because of side effects, compared with 4.1% on placebo. In people with type 2 diabetes, this trial found that a once-daily orforglipron pill led to more weight loss than placebo over 72 weeks, with larger losses at higher doses and gut problems as the main side effects that led people to stop.
Orforglipron 36 mg: 11.2% weight loss at 72 weeks in ATTAIN-1
Randomized trial, human, 2025: Side effects led 5.3 to 10.3% of people on orforglipron to stop treatment, versus 2.7% on placebo, and the most common were gut-related effects that were mostly mild to moderate. In a large 72-week trial, daily oral orforglipron led to more weight loss than placebo at every dose tested, with gut side effects as the most common problem.
Orforglipron: food lowered drug exposure by 17.6% to 23.7%
Clinical trial, human, 2024: Most side effects were gut-related, and there were no serious adverse events or deaths in either study. They measured blood levels and safety, not weight loss or blood sugar, so the authors' view that food won't change how well the drug works was not directly tested.
Questions people ask
What are the side effects of orforglipron?
The side effects most commonly reported for orforglipron are nausea, constipation and diarrhea, among 8 the library lists; the library’s evidence on it includes controlled trials in people.
Do orforglipron’s side effects come from human studies?
The library rates the evidence on orforglipron as established, and the library’s evidence on it includes controlled trials in people.
Which orforglipron side effects are its own?
Among the metabolic & GLP-1 compounds, the library lists burping for orforglipron alone.
Does orforglipron interact with other medicines?
The library’s interaction note on orforglipron begins: The label advises against combining it with another GLP-1 drug.